Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit — MS-COUGH  

Multiple Sclerosis Clinical Trial

Official title: Self-administered Hyperinsufflation Chest Mobilization Randomized Study on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit

Status Recruiting

Clinical Trial Summary

In patients with neuromuscular disease, chest mobilization by hyperinsufflation slows respiratory decline by almost 80% compared to controls, and prevents complications like pneumonia, atelectasis and respiratory distress.

This insufflation technique improves the airway clearance and reduces the need for invasive ventilation. It also improves CV and DEPtoux in patients with neuromuscular pathology

Clinical Trial Description

During multiple sclerosis (MS), although expiratory involvement and reduced sputum capacity are predominant, automated techniques of hyperinsufflation and in-exsufflation remain underused and undervalued. A single retrospective study suggests a decrease in the decline in respiratory function with regular manual hyperinsufflation.

Evidence of a benefit of chest mobilization by hyperinsufflation by a controlled trial is therefore necessary before recommending its use in MS. ;

Related Conditions & MeSH terms

• Multiple Sclerosis
• Respiratory Tract Infections
• Sclerosis

• NCT number: NCT04563832
• Study type: Interventional
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Jonathan LEVY, Dr
• Phone: +33 147107900
• Email: jonathan.levy2@aphp.fr
• Status: Recruiting
• Phase: N/A
• Start date: November 25, 2021
• Completion date: October 2022